NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

CoImmune is involved in the development and manufacture of cell-based therapeutics within the healthcare sector. The company works on treatments for cancer, autoimmune, and inflammatory diseases. Its clientele includes sectors seeking medical therapies for complex conditions. CoImmune was formerly known as Argos Therapeutics. It was founded in 1997 and is based in Durham, North Carolina. CoImmune operates as a subsidiary of Genexine and SCM Lifescience.

The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Vasopharm is a company focused on the development of pharmaceuticals within the healthcare sector. The company specializes in creating vasodilator drugs that are designed to improve blood flow and reduce blood pressure. It was founded in 1998 and is based in Wurzburg, Germany.

Intarcia Therapeutics is a biotech company that focuses on the development of biologics and peptides for the treatment of cardio-renal-metabolic diseases. The company's main offerings include a pipeline of long-acting GLP-1 receptor agonists and other peptide-based therapies designed to improve the management of chronic diseases. Intarcia primarily serves sectors in the healthcare industry that are involved with chronic disease management and biopharmaceuticals. It was founded in 1995 and is based in Boston, Massachusetts.

Phytomedics focuses on the development and manufacturing of multi-mechanism and multi-component pharmaceuticals within the healthcare sector. The company uses platform technologies to create its pharmaceutical products. Phytomedics serves the pharmaceutical industry with its drug development. It was founded in 1996 and is based in Jamesburg, New Jersey.